EMEA-000311-PIP06-18

Key facts

Invented name
Stelara
Active substance
Ustekinumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0178/2019
PIP number
EMEA-000311-PIP06-18
Pharmaceutical form(s)
  • Intravenous use
  • Subcutaneous use
Condition(s) / indication(s)
Treatment of Systemic Lupus Erythematosus (SLE)
Route(s) of administration
  • Concentrate for solution for infusion
  • Solution for injection
Contact for public enquiries
Janssen Cilag International NV

Tel. +3214602111
E-mail: contact@Janssen-emea.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating